In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Pharmaceuticals, Inc.

http://www.npsp.com

Latest From NPS Pharmaceuticals, Inc.

EMA Says Yes To Eight New Medicines, Holds Fire On Others

The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.

Europe Approvals

Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU

The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.

Europe Drug Review

EU Decision Time For Albireo’s Rare Liver Disease Drug

Odevixibat, which could become the first drug approved for treating progressive familial intrahepatic cholestasis in children, is up for an opinion from the European Medicines Agency.

Liver & Hepatic Drug Review

Albireo Sets Sights On Rare Disease Model

Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.

Rare Diseases Life Cycle Management
See All

Company Information

UsernamePublicRestriction

Register